The NeuroCytotron utilizes non-invasive, safe tissue engineering
technology to stimulate proteins that aid in the regeneration of
brain cells.
ROCKVILLE, Md., July 3, 2024
/PRNewswire-PRWeb/ -- NeuroCytonix, Inc., today announced that on
May 27, 2024, its subsidiary
NeuroCytonix Mexico received a regulatory approval letter from the
ethical, scientific, and safety committees of Hospital La Mision in
Monterrey, Mexico, to launch a
clinical trial on autism. The study is aptly named "Preliminary
Efficacy and Feasibility of Using the NeuroCytotron to Treat Autism
Spectrum Disorder: A Pilot Study."
We are excited by the potential of our
technology to improve the quality of life of autistic children with
higher support needs. In early index cases, we have been amazed to
see children become calmer, more communicative, focused, and more
engaged in the world around them. - Dr. J. Roberto Trujillo
The launch of this new clinical trial follows the acknowledgment
letter (ref/memorandum number 223300ES450795/2023) sent to
NeuroCytonix by the Mexican regulatory authority COFEPRIS in 2023.
The letter recognized the encouraging results of the rigorous
cerebral palsy trial and motivated NeuroCytonix to apply its
technology to other neurological conditions, developing its
protocol for autism.
Dr. J. Roberto Trujillo, Founder
and CEO of NeuroCytonix, spoke about the new clinical trial,
saying, "We are excited by the potential of our technology to
improve the quality of life of autistic children with higher
support needs. In early index cases, we have been amazed to see
children become calmer, more communicative, focused, and more
engaged in the world around them. We have even seen children move
from special ed classes to general classes with the rest of their
peers. There is still a lot of research to be done to validate our
findings, and this pilot study is part of that effort. We hope our
technology can be a beacon of hope to autistic children and their
families."
See how our index cases responded to the protocol.
About NeuroCytonix
NeuroCytonix is an emerging biotechnology company founded in
January 2017 by Dr. J Roberto Trujillo to develop and harness
transformational medical technologies to regenerate the nervous
system. The Company's technology and related protocols have been
designed to address conditions including stroke, cerebral palsy,
traumatic brain injury, the neurological impacts of COVID-19, and
now, autism. The Company's core technology, the NeuroCytotron,
utilizes non-invasive, safe tissue engineering technology that
stimulates proteins that aid in regenerating brain cells.
The NeuroCytonix technology is based on the work of Dr. Rajah V
Kumar, inventor of the CYTOTRON® and a pioneer for more than 30
years in biophysics, radiobiology, and regenerative tissue
engineering.
NeuroCytonix's founder and CEO is J. Roberto Trujillo, MD ScD. Since receiving his
Doctor of Science degree from Harvard
University — as the first ScD student to combine the study
of neuroscience and virology — he has been a leader in clinical and
basic neuroscience research and molecular virology for brain
diseases. Dr. Trujillo is transforming the healthcare status quo
for neurological conditions once believed to be incurable.
NeuroCytonix has built a state-of-the-art research center in
Monterrey, Mexico. It trained and
directed the clinical research team and successfully ran its first
clinical trial evaluating the safety and efficacy of the treatment
for cerebral palsy.
Link to the complete study on
https://clinicaltrials.gov/study/NCT06477263.
Please visit www.neurocytonix.com for more information.
Contact:
Laurent Lavigne du Cadet
Chief Financial Officer and Chief Operating Officer
llavigne@neurocytonix.com
Media Contact
Laurent Lavigne du Cadet, Chief
Financial Officer and Chief Operating Officer, NeuroCytonix, 1
240-243-6455, llavigne@neurocytonix.com,
www.neurocytonix.com
View original content to download
multimedia:https://www.prweb.com/releases/neurocytonix-launches-clinical-trial-studying-its-neurocytotron-protocol-for-autism-302188252.html
SOURCE NeuroCytonix